ARTICLE | Distillery Therapeutics
FBXL2-mediated EGFR degradation for TKI-resistant NSCLC
December 3, 2021 5:32 PM UTC
DISEASE CATEGORY: Cancer
INDICATION: Non-small cell lung cancer (NSCLC)...
BCIQ Company Profiles
BCIQ Target Profiles
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
DISEASE CATEGORY: Cancer
INDICATION: Non-small cell lung cancer (NSCLC)...
BCIQ Company Profiles
BCIQ Target Profiles
BCIQ Company Profiles
BCIQ Target Profiles